Lilly's obesity pill cut body weight by 11% in key study

Eli Lilly & Co.'s experimental pill helped patients shed roughly 11% of their body weight, about 25 pounds, in a late-stage study that sets the stage for a new entrant to the obesity market next year.

- Bloomberg

The result falls on the lower end of Wall Street's expectations. Investors had hoped Lilly's pill, called orforglipron, would be as effective as Wegovy—the blockbuster weight-loss shot made by Novo Nordisk A/S. Wegovy users lost about 14% to 15% of their weight in pivotal trials, slightly less than those getting Lilly's rival injection Zepbound.